BMRA:NSD-Biomerica, Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 6.38

Change

-0.31 (-4.63)%

Market Cap

USD 0.08B

Volume

0.21M

Average Target Price

USD 12.00 (+88.09%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Biomerica, Inc., a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy that is designed to allow physicians to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms; Helicobacter pylori products; and develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.

Company Website : http://www.biomerica.com

Address : 17571 Von Karman Avenue, Irvine, CA, United States, 92614

Employees : 65

Fiscal Year End : May

Currency: USD

Country : USA

Technical Indicators

Beta : -0.65

52 Week High : 12.75

Short Ratio : 1.39

52 Week Low : 2.05

Shorted Shares : 1,267,669

200 Day Moving Average : 6.67

Shorted Shares Previous Month : 969,164

50 Day Moving Average : 6.71

Shares Held By Insiders : 179.49%

Short Percentage : 11.00%

Shares Held by Institutions : 21.38%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-23 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

-6.02 (-1.28%)

 USD68.65B 105.74 63.53
IDXX IDEXX Laboratories, Inc

-11.69 (-2.18%)

 USD45.87B 80.02 58.76
DXCM DexCom, Inc

-5.28 (-1.28%)

 USD39.63B 81.43 102.56
EXAS Exact Sciences Corporation

-3.61 (-2.54%)

 USD24.07B N/A N/A
GH Guardant Health, Inc

+0.20 (+0.13%)

 USD17.04B N/A N/A
OZON Ozon Holdings PLC

-4.09 (-6.16%)

 USD13.53B N/A N/A
ICLR ICON Public Limited Company

+0.37 (+0.18%)

 USD10.99B 34.62 23.46
NTRA Natera, Inc

+0.08 (+0.07%)

 USD9.48B N/A N/A
PRAH PRA Health Sciences, Inc

+0.43 (+0.34%)

 USD8.17B 37.25 21.13
SYNH Syneos Health, Inc

-0.90 (-1.22%)

 USD7.72B 40.44 20.94

ETFs Containing BMRA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 28.11% 58% F 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.11% 58% F 76% C
Trailing 12 Months  
Capital Gain 130.32% 69% D+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 130.32% 69% D+ 84% B
Trailing 5 Years  
Capital Gain 461.62% 73% C 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 461.62% 73% C 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 52.01% 77% C+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 52.01% 77% C+ 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 73.01% 35% F 17% F
Risk Adjusted Return 71.24% 75% C 84% B
Market Capitalization 0.08B 13% F 16% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 7.38 48% F 27% F
Price / Cash Flow Ratio -18.34 74% C 78% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -61.72% 37% F 19% F
Return on Invested Capital -26.49% 47% F 27% F
Return on Assets -26.37% 33% F 15% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.39 59% F 62% D-
Short Percent 13.14% 11% F 15% F
Beta -0.65 98% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector